title: High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma.
abstract: To investigate the possibility that a hypercoagulable state develops during autologous bone marrow transplantation (BMT), we measured levels of circulating natural anticoagulants and fibrinolytic proteins before and weekly during the hospital course of 18 patients undergoing autologous BMT for Hodgkin's and non-Hodgkin's lymphoma. Patients received either weekly (standard dose group) or daily (high dose group) vitamin K supplements with their total parenteral nutrition. By day 14 there had been a significant drop in protein C activity (mean of 95% of normal to 52%), protein C antigen (mean of 105% of normal to 70%), and antithrombin 3 activity (111% of normal to 83%), and an increase in fibrinogen (471-621 mg/dl) and tissue plasminogen activator (6.9-13.8 ng/ml). No changes were seen in free or total protein S, plasminogen activator inhibitor, prothrombin time or partial thromboplastin time. The decreases in protein C and antithrombin 3 persisted through day 28 after transplantation. The drop in protein C correlated strongly with decrease in serum albumin, suggesting impaired synthesis of these proteins by the liver. No differences were seen in any of these parameters between the standard and high dose groups. Deficiencies in anticoagulant proteins antithrombin 3 and protein C and a rise in fibrinogen without a concomitant improvement in fibrinolytic variables create a potentially hypercoagulable state which may contribute to the thrombotic complications of autologous BMT.
authors.affiliation: Department of Pediatrics, University of Nebraska Medical Center, Omaha 68198-2165.
authors.forename: B
authors.initials: B
authors.lastname: Gordon
authors.forename: W
authors.initials: W
authors.lastname: Haire
authors.forename: A
authors.initials: A
authors.lastname: Kessinger
authors.forename: M
authors.initials: M
authors.lastname: Duggan
authors.forename: J
authors.initials: J
authors.lastname: Armitage
mesh_terms: D000328:Adult; D000990:Antithrombin III / Q000032:analysis* / Q000378:metabolism; D001777:Blood Coagulation / Q000187:drug effects; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D006689:Hodgkin Disease / Q000378:metabolism / Q000601:surgery*; D006801:Humans; D007275:Injections, Intravenous; D008099:Liver / Q000378:metabolism; D008228:Lymphoma, Non-Hodgkin / Q000378:metabolism / Q000601:surgery*; D011486:Protein C / Q000378:metabolism; D020151:Protein C Deficiency; D012709:Serum Albumin / Q000378:metabolism; D013927:Thrombosis / Q000209:etiology; D014182:Transplantation, Autologous; D014812:Vitamin K / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D011486:Protein C; D012709:Serum Albumin; D014812:Vitamin K; D000990:Antithrombin III